Skip to main content
Top
Published in: Familial Cancer 3/2015

Open Access 01-09-2015 | Original Article

A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine

Authors: Maren F. Hansen, Jostein Johansen, Inga Bjørnevoll, Anna E. Sylvander, Kristin S. Steinsbekk, Pål Sætrom, Arne K. Sandvik, Finn Drabløs, Wenche Sjursen

Published in: Familial Cancer | Issue 3/2015

Login to get access

Abstract

In some families there is an increased risk for colorectal cancer, caused by heritable, but often unidentified genetic mutations predisposing to the disease. We have identified the likely genetic cause for disease predisposition in a large family with high burden of colorectal adenomas and carcinomas, in addition to extra-colonic cancers. This family had previously been tested for known cancer susceptibility genes, with negative results. Exome sequencing was used to identify a novel mutation, c.1373A>T (p.Tyr458Phe), in the gene for DNA polymerase epsilon catalytic subunit (POLE). This mutation is located in the active site of the exonuclease domain of the enzyme, and affects a residue that has previously been shown to be important for exonuclease activity. The first predisposing mutation identified in POLE (c.1270C>G, p.Leu424Val) was associated with colorectal cancer only, but another mutation with a broader tumour spectrum (c.1089C>A, p.Asn363Lys) has recently been reported. In the family described in the present study, carriers generally have multiple colorectal adenomas and cancer of colon, pancreas, ovaries and small intestine which represents an important broadening of the tumour spectrum of POLE mutation carriers. We also observe a large phenotypic variation among the POLE mutation carriers in this family, most likely explained by modifying variants in other genes. One POLE mutation carrier has a novel variant in EXO1 (c.458C>T, p.Ala153Val), which may contribute to a more severe phenotype. The findings in this study will have important implications for risk assessment and surveillance of POLE mutation carriers.
Appendix
Available only for authorised users
Literature
13.
go back to reference Van der Auwera GA, Carneiro MO, Hartl C et al (2013) From FastQ data to high-confidence variant calls: the genome analysis toolkit best practices pipeline. In: Bateman A, Pearson WR, Stein LD et al (eds) Current protocols in bioinformatics, 43rd edn. Wiley, Hoboken, pp 1–11 Van der Auwera GA, Carneiro MO, Hartl C et al (2013) From FastQ data to high-confidence variant calls: the genome analysis toolkit best practices pipeline. In: Bateman A, Pearson WR, Stein LD et al (eds) Current protocols in bioinformatics, 43rd edn. Wiley, Hoboken, pp 1–11
18.
go back to reference Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185:862–864CrossRefPubMed Grantham R (1974) Amino acid difference formula to help explain protein evolution. Science 185:862–864CrossRefPubMed
32.
go back to reference Rohlin A, Zagoras T, Nilsson S et al (2014) A mutation in POLE predisposing to a multi-tumour phenotype. Int J Oncol 45:77–81PubMedCentralPubMed Rohlin A, Zagoras T, Nilsson S et al (2014) A mutation in POLE predisposing to a multi-tumour phenotype. Int J Oncol 45:77–81PubMedCentralPubMed
33.
35.
go back to reference Beese LS, Steitz TA (1991) Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J 10:25–33PubMedCentralPubMed Beese LS, Steitz TA (1991) Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J 10:25–33PubMedCentralPubMed
36.
37.
go back to reference Derbyshire V, Grindley ND, Joyce CM (1991) The 3′-5′ exonuclease of DNA polymerase I of Escherichia coli: contribution of each amino acid at the active site to the reaction. EMBO J 10:17–24PubMedCentralPubMed Derbyshire V, Grindley ND, Joyce CM (1991) The 3′-5′ exonuclease of DNA polymerase I of Escherichia coli: contribution of each amino acid at the active site to the reaction. EMBO J 10:17–24PubMedCentralPubMed
38.
go back to reference Abdus Sattar AK, Lin TC, Jones C, Konigsberg WH (1996) Functional consequences and exonuclease kinetic parameters of point mutations in bacteriophage T4 DNA polymerase. Biochemistry 35:16621–16629. doi:10.1021/bi961552q CrossRefPubMed Abdus Sattar AK, Lin TC, Jones C, Konigsberg WH (1996) Functional consequences and exonuclease kinetic parameters of point mutations in bacteriophage T4 DNA polymerase. Biochemistry 35:16621–16629. doi:10.​1021/​bi961552q CrossRefPubMed
39.
go back to reference Soengas MS, Esteban JA, Lázaro JM et al (1992) Site-directed mutagenesis at the Exo III motif of phi 29 DNA polymerase; overlapping structural domains for the 3′-5′ exonuclease and strand-displacement activities. EMBO J 11:4227–4237PubMedCentralPubMed Soengas MS, Esteban JA, Lázaro JM et al (1992) Site-directed mutagenesis at the Exo III motif of phi 29 DNA polymerase; overlapping structural domains for the 3′-5′ exonuclease and strand-displacement activities. EMBO J 11:4227–4237PubMedCentralPubMed
40.
go back to reference Hwang YT, Liu BY, Coen DM, Hwang CB (1997) Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J Virol 71:7791–7798PubMedCentralPubMed Hwang YT, Liu BY, Coen DM, Hwang CB (1997) Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J Virol 71:7791–7798PubMedCentralPubMed
42.
go back to reference Freemont PS, Friedman JM, Beese LS et al (1988) Cocrystal structure of an editing complex of Klenow fragment with DNA. Proc Natl Acad Sci USA 85:8924–8928PubMedCentralCrossRefPubMed Freemont PS, Friedman JM, Beese LS et al (1988) Cocrystal structure of an editing complex of Klenow fragment with DNA. Proc Natl Acad Sci USA 85:8924–8928PubMedCentralCrossRefPubMed
43.
go back to reference Lam WC, Van der Schans EJ, Joyce CM, Millar DP (1998) Effects of mutations on the partitioning of DNA substrates between the polymerase and 3′-5′ exonuclease sites of DNA polymerase I (Klenow fragment). Biochemistry 37:1513–1522. doi:10.1021/bi9720181 CrossRefPubMed Lam WC, Van der Schans EJ, Joyce CM, Millar DP (1998) Effects of mutations on the partitioning of DNA substrates between the polymerase and 3′-5′ exonuclease sites of DNA polymerase I (Klenow fragment). Biochemistry 37:1513–1522. doi:10.​1021/​bi9720181 CrossRefPubMed
49.
go back to reference Spier I, Holzapfel S, Altmüller J et al (2014) Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. doi:10.1002/ijc.29396 PubMed Spier I, Holzapfel S, Altmüller J et al (2014) Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. doi:10.​1002/​ijc.​29396 PubMed
50.
go back to reference Tingstedt B, Weitkämper C, Andersson R (2011) Early onset pancreatic cancer—comparison against matched controls. Ann Gastroenterol 24:206–212PubMedCentralPubMed Tingstedt B, Weitkämper C, Andersson R (2011) Early onset pancreatic cancer—comparison against matched controls. Ann Gastroenterol 24:206–212PubMedCentralPubMed
53.
go back to reference Shen B, Nolan JP, Sklar LA, Park MS (1997) Functional analysis of point mutations in human flap endonuclease-1 active site. Nucleic Acids Res 25:3332–3338PubMedCentralCrossRefPubMed Shen B, Nolan JP, Sklar LA, Park MS (1997) Functional analysis of point mutations in human flap endonuclease-1 active site. Nucleic Acids Res 25:3332–3338PubMedCentralCrossRefPubMed
56.
go back to reference Tran HT, Gordenin DA, Resnick MA (1999) The 3′→5′ exonucleases of DNA polymerases delta and epsilon and the 5′→3′ exonuclease Exo1 have major roles in postreplication mutation avoidance in Saccharomyces cerevisiae. Mol Cell Biol 19:2000–2007PubMedCentralPubMed Tran HT, Gordenin DA, Resnick MA (1999) The 3′→5′ exonucleases of DNA polymerases delta and epsilon and the 5′→3′ exonuclease Exo1 have major roles in postreplication mutation avoidance in Saccharomyces cerevisiae. Mol Cell Biol 19:2000–2007PubMedCentralPubMed
57.
go back to reference Talseth-Palmer BA, Wijnen JT, Brenne IS et al (2013) Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int J Cancer 132:1556–1564. doi:10.1002/ijc.27843 CrossRefPubMed Talseth-Palmer BA, Wijnen JT, Brenne IS et al (2013) Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int J Cancer 132:1556–1564. doi:10.​1002/​ijc.​27843 CrossRefPubMed
62.
go back to reference Meijers-Heijboer H, Wijnen J, Vasen H et al (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308–1314PubMedCentralCrossRefPubMed Meijers-Heijboer H, Wijnen J, Vasen H et al (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308–1314PubMedCentralCrossRefPubMed
Metadata
Title
A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine
Authors
Maren F. Hansen
Jostein Johansen
Inga Bjørnevoll
Anna E. Sylvander
Kristin S. Steinsbekk
Pål Sætrom
Arne K. Sandvik
Finn Drabløs
Wenche Sjursen
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2015
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-015-9803-2

Other articles of this Issue 3/2015

Familial Cancer 3/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine